These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1510 related items for PubMed ID: 24323795

  • 1. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis.
    Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Reilly PA, Siegbahn A, Yusuf S, Wallentin L.
    Circulation; 2014 Mar 04; 129(9):961-70. PubMed ID: 24323795
    [Abstract] [Full Text] [Related]

  • 2. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.
    Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S.
    Circulation; 2011 May 31; 123(21):2363-72. PubMed ID: 21576658
    [Abstract] [Full Text] [Related]

  • 3. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial.
    Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P, Eikelboom J, Brueckmann M, Yusuf S, Connolly SJ.
    Circulation; 2012 Feb 07; 125(5):669-76. PubMed ID: 22215856
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
    Chevalier J, Delaitre O, Hammès F, de Pouvourville G.
    Arch Cardiovasc Dis; 2014 Feb 07; 107(6-7):381-90. PubMed ID: 24973113
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Stroke prevention in atrial fibrillation patients with chronic kidney disease.
    Hart RG, Eikelboom JW, Brimble KS, McMurtry MS, Ingram AJ.
    Can J Cardiol; 2013 Jul 07; 29(7 Suppl):S71-8. PubMed ID: 23790601
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients.
    Prescrire Int; 2012 Feb 07; 21(124):33-6. PubMed ID: 22413715
    [Abstract] [Full Text] [Related]

  • 13. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.
    Zalesak M, Siu K, Francis K, Yu C, Alvrtsyan H, Rao Y, Walker D, Sander S, Miyasato G, Matchar D, Sanchez H.
    Circ Cardiovasc Qual Outcomes; 2013 Sep 01; 6(5):567-74. PubMed ID: 23922182
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
    Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP.
    Ann Intern Med; 2011 Jan 04; 154(1):1-11. PubMed ID: 21041570
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran.
    Barrios V, Escobar C.
    Expert Opin Pharmacother; 2012 Dec 04; 13(18):2649-61. PubMed ID: 23167273
    [Abstract] [Full Text] [Related]

  • 19. Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation.
    Eikelboom JW, Connolly SJ, Hart RG, Wallentin L, Reilly P, Oldgren J, Yang S, Yusuf S.
    J Am Coll Cardiol; 2013 Sep 03; 62(10):900-8. PubMed ID: 23770182
    [Abstract] [Full Text] [Related]

  • 20. Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial.
    Bohula EA, Giugliano RP, Ruff CT, Kuder JF, Murphy SA, Antman EM, Braunwald E.
    Circulation; 2016 Jul 05; 134(1):24-36. PubMed ID: 27358434
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 76.